Codexis Inc
CDXS
查看詳細走勢圖
1.695USD
+0.035+2.11%
交易中 （美東）報價延遲15分鐘
153.03M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+2.11%
5天
+1.50%
1月
+10.06%
6月
-25.98%
今年開始到現在
-64.47%
1年
-67.90%
查看詳細走勢圖
TradingKey Codexis Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
Codexis Inc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名105/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價6.58。中期看，股價處於下降通道。近一個月，市場表現較強，技術面和基本面綜合得分較高，較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Codexis Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
7
分析師
買入
評級
6.583
目標均價
+242.88%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Codexis Inc亮點
亮點風險
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
業績增長期
公司處於發展階段，最新年度總收入59.34M美元
利潤高增長
公司淨利潤處於行業前列，最新年度總收入59.34M美元
估值高估
公司最新PE估值-2.26，處於3年歷史高位
機構減倉
最新機構持股63.79M股，環比減少4.77%
PRFDX持倉
明星投資者PRFDX持倉，最新持倉8.40K股
活躍度增加
近期活躍度增加，過去20天平均換手率0.67
Codexis Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Codexis Inc簡介
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
公司代碼CDXS
公司Codexis Inc
CEOMoore (Alison)
網址https://www.codexis.com/
常見問題
Codexis Inc(CDXS)的當前股價是多少？
Codexis Inc(CDXS)的當前股價是 1.695。
Codexis Inc 的股票代碼是什麼？
Codexis Inc的股票代碼是CDXS。
Codexis Inc股票的52週最高點是多少？
Codexis Inc股票的52週最高點是5.505。
Codexis Inc股票的52週最低點是多少？
Codexis Inc股票的52週最低點是1.520。
Codexis Inc的市值是多少？
Codexis Inc的市值是153.03M。
Codexis Inc的淨利潤是多少？
Codexis Inc的淨利潤為-65.28M。
現在Codexis Inc(CDXS)的股票是買入、持有還是賣出？
根據分析師評級，Codexis Inc(CDXS)的總體評級為買入，目標價格為6.583。
Codexis Inc(CDXS)股票的每股收益（EPS TTM）是多少
Codexis Inc(CDXS)股票的每股收益（EPS TTM）是-0.736。
相關品種
-0.24%
+0.41%
+0.68%
+0.19%
+0.67%
+2.84%
+1.12%
-0.28%
-0.19%
+0.26%
-0.54%
+0.16%
+0.78%
-0.24%
+0.08%
+0.71%
+1.83%
0.00%
+0.92%
+1.57%
